Xywav® (calcium/magnesium/potassium/sodium oxybates) – New indication
August 12, 2021 - Jazz Pharmaceuticals announced the FDA approval of Xywav (calcium/magnesium/potassium/sodium oxybates), for the treatment of idiopathic hypersomnia (IH) in adults.
Download PDF
